163 related articles for article (PubMed ID: 7975207)
1. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.
Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F
Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207
[TBL] [Abstract][Full Text] [Related]
2. Conservation of a hairpin ribozyme sequence in HIV-1 is required for efficient viral replication.
Yamada O; Kraus G; Sargueil B; Yu Q; Burke JM; Wong-Staal F
Virology; 1996 Jun; 220(2):361-6. PubMed ID: 8661387
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
Ramezani A; Ding SF; Joshi S
Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
[TBL] [Abstract][Full Text] [Related]
4. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1.
Yamada O; Yu M; Yee JK; Kraus G; Looney D; Wong-Staal F
Gene Ther; 1994 Jan; 1(1):38-45. PubMed ID: 7584058
[TBL] [Abstract][Full Text] [Related]
5. A novel ribozyme target site located in the HIV-1 nef open reading frame.
Larsson S; Hotchkiss G; Su J; Kebede T; Andäng M; Nyholm T; Johansson B; Sönnerborg A; Vahlne A; Britton S; Ahrlund-Richter L
Virology; 1996 May; 219(1):161-9. PubMed ID: 8623525
[TBL] [Abstract][Full Text] [Related]
6. Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro.
Klebba C; Ottmann OG; Scherr M; Pape M; Engels JW; Grez M; Hoelzer D; Klein SA
Gene Ther; 2000 Mar; 7(5):408-16. PubMed ID: 10694823
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo transduction and expansion of CD4+ lymphocytes from HIV + donors: prelude to a ribozyme gene therapy trial.
Leavitt MC; Yu M; Wong-Staal F; Looney DJ
Gene Ther; 1996 Jul; 3(7):599-606. PubMed ID: 8818647
[TBL] [Abstract][Full Text] [Related]
8. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs.
Konopka K; Düzgüneş N; Rossi J; Lee NS
J Drug Target; 1998; 5(4):247-59. PubMed ID: 9713975
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
Ramezani A; Joshi S
Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
[TBL] [Abstract][Full Text] [Related]
10. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding.
Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F
J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131
[TBL] [Abstract][Full Text] [Related]
11. Design of the hairpin ribozyme for targeting specific RNA sequences.
Hampel A; DeYoung MB; Galasinski S; Siwkowski A
Methods Mol Biol; 1997; 74():171-7. PubMed ID: 9204432
[TBL] [Abstract][Full Text] [Related]
12. Cleavage of the highly conserved hairpin-loop region of HIV-1 by synthetic ribozymes.
Shimayama T; Nishikawa S; Taira K
Nucleic Acids Symp Ser; 1993; (29):177-8. PubMed ID: 8247758
[TBL] [Abstract][Full Text] [Related]
13. Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity.
Kuwasaki T; Hosono K; Takai K; Ushijima K; Nakashima H; Saito T; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1996 Nov; 228(2):623-31. PubMed ID: 8920960
[TBL] [Abstract][Full Text] [Related]
14. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy.
Hörster A; Teichmann B; Hormes R; Grimm D; Kleinschmidt J; Sczakiel G
Gene Ther; 1999 Jul; 6(7):1231-8. PubMed ID: 10455431
[TBL] [Abstract][Full Text] [Related]
15. Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis.
Hnatyszyn H; Spruill G; Young A; Seivright R; Kraus G
Gene Ther; 2001 Dec; 8(24):1863-71. PubMed ID: 11821940
[TBL] [Abstract][Full Text] [Related]
16. Multiple folded conformations of a hammerhead ribozyme domain under cleavage conditions.
Woisard A; Fourrey JL; Favre A
J Mol Biol; 1994 Jun; 239(3):366-70. PubMed ID: 8201618
[TBL] [Abstract][Full Text] [Related]
17. Activities of HIV-RNA targeted ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid.
Ohkawa J; Yuyama N; Taira K
Nucleic Acids Symp Ser; 1992; (27):15-6. PubMed ID: 1289797
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide sequences within the U5 region of the viral RNA genome are the major determinants for an human immunodeficiency virus type 1 to maintain a primer binding site complementary to tRNA(His).
Zhang Z; Kang SM; LeBlanc A; Hajduk SL; Morrow CD
Virology; 1996 Dec; 226(2):306-17. PubMed ID: 8955050
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS.
Manca F; Fenoglio D; Franchin E; Saverino D; Li Pira G; Buffa F; Bignardi D; Del Pup L; Palù G
Gene Ther; 1997 Nov; 4(11):1216-24. PubMed ID: 9425445
[TBL] [Abstract][Full Text] [Related]
20. Hairpin ribozyme specificity in vivo: a case of promiscuous cleavage.
Denman RB
Biochem Biophys Res Commun; 1999 Apr; 257(2):356-60. PubMed ID: 10198217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
